한글목차

PF-07923568은 경구용 생물학적으로 이용 가능한 호흡기세포융합바이러스(RSV) 융합 억제제이며, Reviral의 물성 지향적 히트 프로파일링 운동에서 도출된 히트 기반 리드 최적화 과정을 통해 확인되었습니다. 이 최적화 과정에는 전임상 및 임상 평가 단계에서의 화합물 활용과 함께 최적화 단계에서 제약 화학 및 바이러스학과의 공동 연구를 수행하는 여러 계약 기관과의 협업이 포함됩니다.

이 화합물은 RSV 바이러스와 숙주 세포의 융합을 억제하는 경구용 억제제로, 현재 성인과 소아를 대상으로 한 임상 2상 개발 단계에 있습니다.

앞으로 몇 년동안 호흡기세포융합바이러스(RSV) 시장 시나리오는 전 세계적으로 광범위한 조사와 의료비 지출 증가로 인해 변화할 것으로 예상됩니다. 각 업체들은 질환을 치료/개선하기 위한 새로운 접근법에 초점을 맞춘 치료법을 개발하고, 과제를 평가하고, PF-07923568의 우위에 영향을 미칠 수 있는 기회를 모색하고 있으며, RSV에 대한 다른 신흥 제품이 PF-07923568과 치열한 시장 경쟁을 벌일 것으로 예상되고 있다, 가까운 시일 내에 후발 신약이 출시되면 시장에 큰 영향을 미칠 것으로 예상됩니다.

이 보고서는 주요 7개국의 호흡기세포융합바이러스(RSV) 치료제 PF-07923568 시장에 대해 조사했으며, 시장 개요, 경쟁 구도, 2032년까지 시장 규모 예측, 국가별 시장 분석 등의 정보를 전해드립니다.

목차

제1장 보고서 서론

제2장 RSV 치료제 PF-07923568개 요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계 신흥 치료법)

제5장 PF-07923568 시장 평가

• RSV 치료제 PF-07923568 시장 전망
• 주요 7개국 분석
  • 주요 7개국의 RSV 치료제 PF-07923568 시장 규모
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight에 대해

제12장 보고서 구입 옵션

영문목차

"PF-07923568 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about PF-07923568 for Respiratory syncytial virus (RSV) in the seven major markets. A detailed picture of the PF-07923568 for RSV in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the PF-07923568 for RSV. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the PF-07923568 market forecast analysis for RSV in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in RSV.

Drug Summary:

PF-07923568 is an orally bioavailable inhibitor of respiratory syncytial virus (RSV) fusion that was identified after a lead optimization process based upon hits that originated from a physical property directed hit profiling exercise at Reviral. This exercise encompassed collaborations with a number of contract organizations with collaborative medicinal chemistry and virology during the optimization phase in addition to those utilized as the compound proceeded through preclinical and clinical evaluation.

It is an orally administered inhibitor designed to block fusion of the RSV virus to the host cell currently in Phase II clinical development for both adult and pediatric populations.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the PF-07923568 description, mechanism of action, dosage and administration, research and development activities in Respiratory syncytial virus (RSV).
• Elaborated details on PF-07923568 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the PF-07923568 research and development activities in RSV across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around PF-07923568.
• The report contains forecasted sales of PF-07923568 for RSV till 2032.
• Comprehensive coverage of the late-stage emerging therapies for RSV.
• The report also features the SWOT analysis with analyst views for PF-07923568 in RSV.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

PF-07923568 Analytical Perspective by DelveInsight

• In-depth PF-07923568 Market Assessment

This report provides a detailed market assessment of PF-07923568 for Respiratory syncytial virus (RSV) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

• PF-07923568 Clinical Assessment

The report provides the clinical trials information of PF-07923568 for RSV covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Respiratory syncytial virus (RSV) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence PF-07923568 dominance.
• Other emerging products for RSV are expected to give tough market competition to PF-07923568 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of PF-07923568 in RSV.
• Our in-depth analysis of the forecasted sales data of PF-07923568 from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the PF-07923568 in RSV.

Key Questions:

• What is the product type, route of administration and mechanism of action of PF-07923568?
• What is the clinical trial status of the study related to PF-07923568 in Respiratory syncytial virus (RSV) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the PF-07923568 development?
• What are the key designations that have been granted to PF-07923568 for RSV?
• What is the forecasted market scenario of PF-07923568 for RSV?
• What are the forecasted sales of PF-07923568 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to PF-07923568 for RSV?
• Which are the late-stage emerging therapies under development for the treatment of RSV?

Table of Contents

1. Report Introduction

2. PF-07923568 Overview in RSV

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. PF-07923568 Market Assessment

• 5.1. Market Outlook of PF-07923568 in RSV
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of PF-07923568 in the 7MM for RSV
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of PF-07923568 in the United States for RSV
  • 5.3.2. Market Size of PF-07923568 in Germany for RSV
  • 5.3.3. Market Size of PF-07923568 in France for RSV
  • 5.3.4. Market Size of PF-07923568 in Italy for RSV
  • 5.3.5. Market Size of PF-07923568 in Spain for RSV
  • 5.3.6. Market Size of PF-07923568 in the United Kingdom for RSV
  • 5.3.7. Market Size of PF-07923568 in Japan for RSV

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options